First‑Line Therapy and Management of Vaginal Lichen Sclerosus

First‑Line Pharmacologic Regimen

The British Association of Dermatologists recommends clobetasol propionate 0.05 % ointment applied once daily for the first month, then every other day during the second month, and twice weekly during the third month, together with non‑irritant soap substitutes and barrier preparations. Evidence strength not specified. 1

Patients should avoid all fragranced or irritant products on the affected area while using topical therapy. Evidence strength not specified. 1

Before initiating treatment, clinicians should confirm the diagnosis of vaginal lichen sclerosus by clinical assessment or, when needed, histological biopsy to exclude vulvar intra‑epithelial neoplasia or malignancy. Evidence strength not specified. 1

The guideline advises that clinicians educate patients on proper use of the ultrapotent steroid, including the amount to apply, the anatomical sites for application, and safety principles to mitigate side‑effect concerns. Evidence strength not specified. 1

Mandatory follow‑up is required to evaluate treatment response and guide long‑term management. Evidence strength not specified. 1
Reassessment should occur at 3 months after completing the initial 3‑month tapering course. Evidence strength not specified. 1
If active disease persists, continue clobetasol propionate 0.05 % until disease control is achieved. Evidence strength not specified. 1
Maintenance dosing should be titrated to control symptoms and resolve skin thickening and ecchymosis, acknowledging that residual pallor may remain. Evidence strength not specified. 1

For lesions resistant to topical therapy, intralesional triamcinolone (10–20 mg) may be considered, but only after biopsy has excluded intra‑epithelial neoplasia or malignancy. Evidence strength not specified. 1
Patients who do not respond to standard topical steroids should be referred to a specialist vulval clinic for further evaluation and management. Evidence strength not specified. 1

Before attributing lack of response to medication failure, clinicians must evaluate patient compliance and correct application technique, as these are common reasons for perceived resistance. Evidence strength not specified. 1